112 related articles for article (PubMed ID: 32750502)
1. Impact of age on efficacy and early mortality of initial sequential treatment versus upfront combination chemotherapy in patients with metastatic colorectal cancer: a subgroup analysis of a phase III trial (AIO KRK0110, XELAVIRI study).
Kurreck A; Heinemann V; Fischer von Weikersthal L; Decker T; Kaiser F; Uhlig J; Schenk M; Freiberg-Richter J; Peuser B; Denzlinger C; Graeven U; Schwaner I; Stahler A; Heinrich K; Jung A; Held S; von Einem JC; Stintzing S; Giessen-Jung C; Modest DP
Eur J Cancer; 2020 Sep; 137():81-92. PubMed ID: 32750502
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110).
Boukovala M; Modest DP; Ricard I; Fischer von Weikersthal L; Decker T; Vehling-Kaiser U; Uhlig J; Schenk M; Freiberg-Richter J; Peuser B; Denzlinger C; Peveling Genannt Reddemann C; Graeven U; Schuch G; Schwaner I; Heinrich K; Neumann J; Jung A; Held S; Stintzing S; Heinemann V; Michl M
ESMO Open; 2024 May; 9(5):103374. PubMed ID: 38744100
[TBL] [Abstract][Full Text] [Related]
3. Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110).
Modest DP; Fischer von Weikersthal L; Decker T; Vehling-Kaiser U; Uhlig J; Schenk M; Freiberg-Richter J; Peuser B; Denzlinger C; Peveling Genannt Reddemann C; Graeven U; Schuch G; Schwaner I; Stahler A; Jung A; Kirchner T; Held S; Stintzing S; Giessen-Jung C; Heinemann V;
J Clin Oncol; 2019 Jan; 37(1):22-32. PubMed ID: 30388045
[TBL] [Abstract][Full Text] [Related]
4. First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110).
Stahler A; Modest DP; Fischer von Weikersthal L; Kaiser F; Decker T; Held S; Graeven U; Schwaner I; Denzlinger C; Schenk M; Kurreck A; Heinrich K; Gießen-Jung C; Neumann J; Kirchner T; Jung A; Stintzing S; Heinemann V
Eur J Cancer; 2022 Sep; 173():194-203. PubMed ID: 35940054
[TBL] [Abstract][Full Text] [Related]
5. Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial).
Stahler A; Heinemann V; Schuster V; Heinrich K; Kurreck A; Gießen-Jung C; Fischer von Weikersthal L; Kaiser F; Decker T; Held S; Graeven U; Schwaner I; Denzlinger C; Schenk M; Neumann J; Kirchner T; Jung A; Kumbrink J; Stintzing S; Modest DP
Eur J Cancer; 2021 Nov; 157():71-80. PubMed ID: 34507244
[TBL] [Abstract][Full Text] [Related]
6. Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110).
Heinrich K; Modest DP; Ricard I; Fischer von Weikersthal L; Decker T; Kaiser F; Graeven U; Uhlig J; Schenk M; Freiberg-Richter J; Peuser B; Denzlinger C; Giessen-Jung C; Stahler A; Michl M; Held S; Jung A; Kirchner T; Stintzing S; Heinemann V
Eur J Cancer; 2021 Apr; 147():128-139. PubMed ID: 33647548
[TBL] [Abstract][Full Text] [Related]
7. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J
Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157
[TBL] [Abstract][Full Text] [Related]
8. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A;
Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906
[TBL] [Abstract][Full Text] [Related]
9. Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study).
Nakayama G; Mitsuma A; Sunagawa Y; Ishigure K; Yokoyama H; Matsui T; Nakayama H; Nakata K; Ishiyama A; Asada T; Umeda S; Ezaka K; Hattori N; Takami H; Kobayashi D; Tanaka C; Kanda M; Yamada S; Koike M; Fujiwara M; Fujii T; Murotani K; Ando Y; Kodera Y
Oncologist; 2018 Aug; 23(8):919-927. PubMed ID: 30049885
[TBL] [Abstract][Full Text] [Related]
10. The Role of Maintenance Strategies in Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis of Randomized Clinical Trials.
Sonbol MB; Mountjoy LJ; Firwana B; Liu AJ; Almader-Douglas D; Mody K; Hubbard J; Borad M; Ahn DH; Murad MH; Bekaii-Saab T
JAMA Oncol; 2020 Mar; 6(3):e194489. PubMed ID: 31855256
[TBL] [Abstract][Full Text] [Related]
11. XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.
Uygun K; Bilici A; Kaya S; Oven Ustaalioglu BB; Yildiz R; Temiz S; Seker M; Aksu G; Cabuk D; Gumus M
Asian Pac J Cancer Prev; 2013; 14(4):2283-8. PubMed ID: 23725128
[TBL] [Abstract][Full Text] [Related]
12. Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study.
Artaç M; Coşkun HŞ; Dane F; Karabulut B; Korkmaz L; Karaağaç M; Çabuk D; Karabulut S; Faruk Aykan N; Doruk H; Avcı N; Turhal NS
J Gastrointest Cancer; 2016 Sep; 47(3):264-72. PubMed ID: 27126591
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group.
Giessen C; Graeven U; Laubender RP; Modest DP; Schulz C; Porschen R; Schmiegel W; Reinacher-Schick A; Hegewisch-Becker S; Stintzing S; Heinemann V
Ann Oncol; 2013 Dec; 24(12):3051-5. PubMed ID: 24130263
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results.
Aparicio T; Bouché O; Taieb J; Maillard E; Kirscher S; Etienne PL; Faroux R; Khemissa Akouz F; El Hajbi F; Locher C; Rinaldi Y; Lecomte T; Lavau-Denes S; Baconnier M; Oden-Gangloff A; Genet D; Paillaud E; Retornaz F; François E; Bedenne L;
Ann Oncol; 2018 Jan; 29(1):133-138. PubMed ID: 29045659
[TBL] [Abstract][Full Text] [Related]
15. Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy-Analysis of the Phase 3 XELAVIRI Trial.
Kurreck A; Heinemann V; Fischer von Weikersthal L; Decker T; Kaiser F; Uhlig J; Schenk M; Freiberg-Richter J; Peuser B; Denzlinger C; Graeven U; Heinrich K; Held S; Stahler A; Alig AHS; Jelas I; von Einem JC; Stintzing S; Giessen-Jung C; Modest DP
Front Oncol; 2022; 12():751453. PubMed ID: 35251955
[TBL] [Abstract][Full Text] [Related]
16. A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer.
Yamaguchi K; Taniguchi H; Komori A; Narita Y; Nitta S; Nomura M; Kadowaki S; Takahari D; Ura T; Andoh M; Muro K; Mori K; Igarashi Y
BMC Cancer; 2015 Aug; 15():601. PubMed ID: 26311588
[TBL] [Abstract][Full Text] [Related]
17. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
[TBL] [Abstract][Full Text] [Related]
18. aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.
Fujita Y; Taguri M; Yamazaki K; Tsurutani J; Sakai K; Tsushima T; Nagase M; Tamagawa H; Ueda S; Tamura T; Tsuji Y; Murata K; Taira K; Denda T; Moriwaki T; Funai S; Nakajima TE; Muro K; Tsuji A; Yoshida M; Suyama K; Kurimoto T; Sugimoto N; Baba E; Seki N; Sato M; Shimura T; Boku N; Hyodo I; Yamanaka T; Nishio K
Oncologist; 2019 Mar; 24(3):327-337. PubMed ID: 30425180
[TBL] [Abstract][Full Text] [Related]
19. Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer.
Aparicio T; Bouché O; Francois E; Retornaz F; Barbier E; Taieb J; Kirscher S; Etienne PL; Faroux R; Khemissa Akouz F; El Hajbi F; Locher C; Rinaldi Y; Lecomte T; Lavau-Denes S; Baconnier M; Oden-Gangloff A; Genet D; Bedenne L; Paillaud E;
Eur J Cancer; 2018 Jul; 97():16-24. PubMed ID: 29777975
[TBL] [Abstract][Full Text] [Related]
20. Capecitabine Plus Oxaliplatin and Bevacizumab, Followed by Maintenance Treatment With Capecitabine and Bevacizumab for Patients Aged > 75 Years With Metastatic Colorectal Cancer.
Petrioli R; Francini E; Cherri S; Torre P; Fiaschi AI; Miano ST; Marrelli D; Rovello F; Francini G
Clin Colorectal Cancer; 2018 Dec; 17(4):e663-e669. PubMed ID: 30153975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]